The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.
about
Diagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workupSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowTransformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.Transformation of follicular lymphoma to double hit B-cell lymphoma causing hypercalcemia in a 69-year-old female: a case report and review of the literature.BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaTransformation of follicular lymphomaElevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Cell of origin of transformed follicular lymphomaSuperior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantationRates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature.XV. Clinical aspects of transformed lymphoma.Follicular lymphomas and their transformation: Past and current research.Rituximab for the treatment of follicular lymphoma.Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.Association of β2-microglobulin with the prognosis of non-Hodgkin's lymphoma: a meta analysis.Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.FDG-PET in Follicular Lymphoma ManagementPrimary gastrointestinal lymphoma.The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.Incidence, risk factors and outcome of histological transformation in follicular lymphoma.Transformed follicular lymphoma.Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.Current prognostic and predictive factors in follicular lymphoma.Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.Unmet needs in the first-line treatment of follicular lymphoma.Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics.A case of diffuse large B-cell lymphoma transformed from primary duodenal follicular lymphoma.Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.
P2860
Q26773194-0066FB60-4038-4727-A0F0-AFDB4635BACCQ28073262-E918765D-FD79-4081-95EF-81CC9EF274ADQ33670880-F1534C73-D44D-40E3-A2F5-FDBD96BD13BEQ33759661-0B11D72E-FF0F-4631-AF97-A52562A2AA67Q33766616-0A918AC2-8CDA-4CDB-AB57-78E2C7C53C6DQ34064956-120AC2A4-A40C-4E7F-869A-82ACF2CF0636Q35004965-0C7CAB05-71F6-49AB-99D8-D40E0DAA6650Q35038729-18411FDE-74E6-4347-BFD7-707CDB074E95Q35056309-7E2C0D68-96A1-4C3B-A2D9-A6F3B289DC23Q35115650-85DC9A82-6128-401F-8675-CDC75EE89CE1Q35166811-F5DDEA68-9F8B-48DD-A07F-328CF4E0BCF4Q35979057-B43E8CA4-4DCF-4A50-9614-72D98AE0DC90Q36225164-FCEF2A19-A923-4C21-82B3-F5FCC24A6B7BQ36837765-73A8A228-D300-4AB7-91A7-50964685956CQ37132380-489C1CDE-3DF8-4B1D-9124-EF09896A2A33Q37829460-4BABD534-134C-40ED-9070-07FA5E7A1FCEQ38032198-7743A997-FE94-42C8-A3D7-FE7173CB5DD4Q38051428-66440EC8-70E2-4768-9CA2-93A819C63485Q38116141-8C7BDFA2-A657-449D-93FE-DFA67A07C7AAQ38524020-F87DF2EA-FE71-4638-9571-5C593E44B145Q39290214-9C6A9DDB-C8CE-4B0A-B1EE-43554DBA1321Q39360775-410B8CE0-B867-4EAB-81FD-92FF8B29209BQ40374056-2ED74C0A-4DE8-4964-B3D5-6792559698E5Q41045903-7CE5C8D8-891E-4B4B-ADCD-2F474A5D9E08Q41489053-8F3ABE6E-0C5B-4806-853E-F0EA478CAE4BQ41840128-EDBDC294-2983-41CF-824B-A56F32C7197DQ42010612-1E6F0FF7-F253-4920-B196-90311326616BQ42174931-A44E30EE-A85B-4A4A-BE82-DCB909D1AE5AQ43704071-3D5DD10C-D15C-47B9-9587-9ED85C5951FBQ45286370-953495B1-42CF-488C-86EB-ECF88F0E6A17Q47771789-6F4B79AF-921F-44D4-AFEE-BDE10D7A095DQ47984316-C0941BEE-8E7B-4ACD-875E-111E0DA92427Q48185856-9D24A424-1753-454B-995D-116915FF7F74Q48726057-827C22D8-922C-4B95-B698-7B7B8AB2E798Q50089414-B4E665BA-2751-4FE1-B11A-5374E140D20EQ50710717-A86B0989-6632-4C69-A7A9-1A9434ED7431Q50942435-87B355F1-A208-4F4B-9AD0-E56EFE920780Q51057764-4B474E78-3E73-4EBA-95CA-7C2BDECF6B8AQ53460739-4778EEAD-3452-4BE6-833F-14E6981027DD
P2860
The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The Follicular Lymphoma Intern ...... mation in follicular lymphoma.
@en
The Follicular Lymphoma International Prognostic Index
@nl
type
label
The Follicular Lymphoma Intern ...... mation in follicular lymphoma.
@en
The Follicular Lymphoma International Prognostic Index
@nl
prefLabel
The Follicular Lymphoma Intern ...... mation in follicular lymphoma.
@en
The Follicular Lymphoma International Prognostic Index
@nl
P2093
P50
P356
P1433
P1476
The Follicular Lymphoma Intern ...... rmation in follicular lymphoma
@en
P2093
A López-Guillermo
A Martínez
E Montserrat
N Villamor
S Mercadal
P304
P356
10.1093/ANNONC/MDL162
P577
2006-08-28T00:00:00Z